Data Characteristics
Recombinant protein pharmacovigilance data primarily originates from clinical trial reports, real-world evidence (RWE), post-market surveillance reports, and medical literature. This data typically combines structured and unstructured documents. Structured data includes fields from adverse drug reaction (ADR) reporting systems, such as patient demographics, medication history, adverse event descriptions, severity, and outcomes. This data updates frequently, potentially daily or in real-time. Unstructured data often consists of clinician notes, case reports, and full research papers. These contain extensive free-text descriptions with critical information like recombinant protein type, dosage, administration route, concomitant medications, and specific immune responses (e.g., antibody production). Document structures are complex, potentially including multi-level headings, figures, abbreviations, and specialized terminology. Field names and units can vary across data sources. For example, dosage units might be mg, μg/kg, or IU, and adverse event coding systems might use MedDRA or WHO-ART.
Constraints on Citation and Traceability
The multi-source and complex nature of recombinant protein pharmacovigilance data imposes specific constraints on citation and traceability. First, the mix of structured and unstructured data requires a citation system capable of both precise field matching and semantic understanding. This ensures potential adverse events extracted from free text correspond to original reports. Second, varying data update frequencies mean traceability must consider data timeliness. This avoids citing outdated or corrected information. For instance, clinical trial data might be supplemented or revised by new real-world data post-market. Document complexity, especially for lengthy medical literature, requires a chunking strategy that does not break critical context, such as specific immunogenicity information for recombinant proteins. Furthermore, differing field names and inconsistent coding systems across data sources necessitate a unified mapping mechanism for traceability. This ensures the accuracy and comparability of cited content. For example, a MedDRA code for acute anaphylaxis should trace back to the original report's description of generalized rash with dyspnea.
Configuration Guidelines
| Configuration Item | Recommended Value | Rationale | ||
|---|---|---|---|---|
Chunk size (Chunk Length) | 500–800 characters (characters) | Balances semantic completeness with recall efficiency, preventing truncation of recombinant protein-specific descriptions. | ||
Recall count (Retrieval Count) | Top 10–15 entries (top 10–15) | Covers a wider range of potential adverse event descriptions and relevant context, addressing complex medical texts. | ||
Similarity threshold (Similarity Threshold) | 0.75–0.85 | Ensures retrieved content is highly relevant to the query intent, reducing interference from irrelevant information. | ||
Rerank result count (Reranked Return Count) | Top 5 entries (top 5) | Focuses on the most relevant citation sources, improving user efficiency in obtaining key information. | ||
Citation Content Template (Citation Content Template) | `document name: {{title}} | Source: {{source}} | description: {{chunkText}}` | Clearly displays the document title, data source, and specific text snippet of the cited content, facilitating quick user assessment. |
PARSE_FILE_TIMEOUT_SECONDS | 600 seconds (seconds) | Accommodates parsing time for large clinical reports or medical literature, preventing parsing failures due to timeouts. |
Common Pitfalls
- AI responses lack critical citations or contain incorrect citations. This manifests as response content not matching original data or citation links pointing to irrelevant documents. The cause is chunk granularity being too large or too small, leading to critical information dilution or context loss.
- When users query specific recombinant protein adverse reactions, relevant literature is not retrieved. This manifests as an insufficient or empty result set. The cause is insufficient consideration of professional terminology and abbreviation variations in the knowledge base index, leading to low retrieval matching.
- Citation sources display as
UnknownorN/A. This manifests as empty citation source fields. The cause is failure to correctly parse or store document metadata during data ingestion, such as document titles and original source links.
Validation Steps
- For different types of recombinant proteins (e.g., monoclonal antibodies, fusion proteins), use typical adverse reaction query statements. Verify whether the content cited in AI responses accurately points to relevant paragraphs in original literature or reports, and check if the citation context is complete.
- Select a batch of original data containing key fields such as dosage, administration route, and specific immune responses. Validate whether the AI can correctly identify and cite the precise values of these fields when answering related questions, and ensure unit consistency.
- Simulate data update scenarios. For example, add a new adverse event report to the knowledge base, then query the recombinant protein adverse events involved in that report. Verify whether the AI response can timely cite this latest data and check if its traceability path is clear.
Note: The values provided are common starting points and should be measured against specific samples.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.